Continuous Intravenous Infusion Recombinant Human Endostatin Combined with Concurrent Chemoradiation Therapy in Unresectable Stage III Non–small Lung Cancer—Results of a Multicenter Phase 2 Study (NCT01733589)
Y. R. Zhai,Z. Hui,H. Ma,L. Zhao,D. Li,J. Liang,L. Xu,N. Bi,B. Chen,Y. Tang,Z. Zhou,M. Chen,L. Wang
DOI: https://doi.org/10.1016/j.ijrobp.2017.06.248
2017-01-01
Abstract:Concurrent radiotherapy is the standard treatment of unresectable stage III non-small lung cancer (NSCLC) but with unsatisfied results. Tumor angiogenesis is one of the most important targets for novel agents’ exploration. Recombinant human endostatin, an angiogenesis blocker, has been indicated to normalize the tumor vasculature to make it more efficient for oxygen delivery, thereby provide a window of opportunity for enhanced sensitivity to radiation treatment. To evaluate the efficacy and safety of the addition of continuous intravenous infusion of recombinant human endostatin to concurrent chemoradiotherapy in inoperable stage III NSCLC, we designed this phase 2 study. This trial was approved by the institutional ethics committees of the four participating institutions. The study was registered on the website of ClinicalTrials.gov (NCT01733589).The eligible patients should meet the following criteria before treatment: untreated histologically or cytologically diagnosed NSCLC, inoperable stage IIIA or IIIB according to AJCC seventh staging system, performance score of 0 to 1, blood coagulation is normal. Patients with preexisting bleeding diatheses were excluded. All of the enrolled patients received thoracic radiation with dose of 60-66 Gy, continuous intravenous infusion of recombinant human endostain (7.5 mg/m2/24 h, 120 h, d-6-d-2, d8-d12, d22-d26, d36-d40, from the beginning of radiotherapy) and two cycles of etoposide (50 mg/m2, d1-d5, d29-d33) plus cisplatin (50 mg/m2, d1, d8, d29, d36). The primary endpoint was progression free survival (PFS) and the secondary endpoints were response, overall survival (OS), local regional free survival (LRFS) and toxicities. Calculating with 20% bilateral Z test (alpha = 0.05, beta = 0.2), 72 patients were needed. From November 2012 to June 2015, seventy-three patients were enrolled and 67 patients were assessable. Fifty-six patients were male and 11 patients were female. The median age was 59 years old. The majority (65.7%) of the patients were diagnosed as squamous cell carcinoma. Severe adverse events were observed in 2 patients (1 hemoptysis and 1 pneumonia). The most common adverse events was leucopenia (95.5%, Grade 3-4:44.8%). The complete response and partial response rate were 11.9% and 64.2%, respectively. The median follow-up time was 37.1 months (20.1-52.1 months). The median time of OS, PFS, and LRFS was 34.7 months, 13.3 months and 27.1 months respectively. The 1-, 2-, and 3-year PFS were 50.7%, 34.8%, and 28.2%, OS were 82.1%, 59.9%, and 47.7%, and LRFS were 72.7%, 54.7%, and 49.9%, respectively. The addition of continuous intravenous human recombinant endostatin to concurrent chemoradiotherapy is effective and tolerable in unresectable stage III NSCLC. Further randomized phase III study is warranted.